Arax Advisory Partners’s Immunome IMNM Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$2.47K Buy
115
+1
+0.9% +$25 ﹤0.01% 4854
2026
Q2
$2.42K Buy
+114
New +$2.44K ﹤0.01% 4778
2026
Q1
– Sell
-19
Closed -$408 – 4060
2025
Q4
$408 Sell
19
-101
-84% -$1.77K ﹤0.01% 3636
2025
Q3
$1.41K Buy
+120
New +$1.19K ﹤0.01% 3182
2025
Q2
– Sell
-69
Closed -$465 – 3126
2025
Q1
$465 Buy
+69
New +$662 ﹤0.01% 2543

Other funds holding IMNM

Arax Advisory Partners's IMNM Position: Q3 2026 in Review

Arax Advisory Partners increased its Immunome (IMNM) stake by 0.88% in Q3 2026, buying an estimated $25 and bringing the position to 115 shares worth $2.47K. The position accounts for ﹤0.01% of the portfolio, ranked #4854.

Arax Advisory Partners first reported a position in IMNM in Q1 2025 and has held it in 5 quarters since. 211 funds tracked by Wall St. Rank hold IMNM as of Q3 2026.

  • Arax Advisory Partners held 115 shares of Immunome worth $2.47K as of Q3 2026.
  • Arax Advisory Partners bought 1 Immunome share in Q3 2026, an estimated $25.
  • Immunome made up ﹤0.01% of Arax Advisory Partners's portfolio in Q3 2026, its #4854 holding.
  • Arax Advisory Partners first reported a position in Immunome in Q1 2025 and has held it in 5 quarters since.
  • 211 funds tracked by Wall St. Rank held Immunome as of Q3 2026.

Based on Arax Advisory Partners's 13F filing for Q3 2026, filed 12 Nov 2026.